Trial Profile
A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2018
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 17 Feb 2009 Planned end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 17 Feb 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 19 Jan 2009 New trial record.